PrPc Antagonists Block Amyloid-Beta Oligomer Binding

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Alzheimer's disease, particularly those targeting soluble Aβ-oligomers, lack specificity due to unknown disease-mediating receptors, and existing therapies fail to effectively inhibit synaptic dysfunction and improve memory retention.

Innovation Solution

Administration of PrPc antagonists, including soluble PrPc polypeptides, anti-PrPc antibodies, PrPc antagonist polynucleotides, or aptamers, which specifically target the cellular prion protein (PrPc) to inhibit Aβ-oligomer binding and reduce PrPc-mediated synaptic dysfunction, thereby enhancing memory retention and treating Alzheimer's disease.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing treatments targeting soluble Aβ-oligomers are used, then some effect on Alzheimer's disease is achieved, but the treatments lack specificity due to unknown disease-mediating receptors

Engineering Contradiction:

Improvespecificity of treatmentVSAvoidunknown disease-mediating receptor

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent identifies PrPc as the intermediary receptor that mediates Aβ-oligomer binding and synaptic dysfunction. By targeting this previously unknown mediator, the treatment achieves high specificity for the disease mechanism while resolving the information gap about the receptor identity.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces non-specific treatments with a targeted molecular approach using PrPc antagonists. This substitution enables precise intervention at the receptor level, transforming the treatment mechanism from broad and non-specific to targeted and specific.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If existing therapies are used to inhibit synaptic dysfunction, then some treatment effect is achieved, but memory retention is not effectively improved

Engineering Contradiction:

Improveefficacy of treatmentVSAvoidimprovement in memory retention

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent extracts and targets the specific functional component (PrPc receptor) responsible for synaptic dysfunction. By isolating and blocking this specific target, the treatment achieves precise control over the disease mechanism, resulting in effective inhibition of synaptic dysfunction and improvement in memory retention.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the target parameter from non-specific Aβ-oligomer reduction to specific PrPc receptor blocking. This parameter change enables precise modulation of the disease mechanism, transforming treatment efficacy into specific improvement of memory retention functions.

Inventive Principle:

Principle #35Parameter changes

3Adaptability or versatility

If non-specific treatments are used, then broader coverage is achieved, but therapeutic specificity and efficacy are reduced

Engineering Contradiction:

Improvecoverage of treatmentVSAvoidspecificity of treatment

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent segments the treatment approach by identifying and targeting the specific PrPc receptor component within the broader Aβ-oligomer pathology. This segmentation enables selective intervention at the receptor level, achieving high therapeutic specificity while maintaining relevance to the broader disease context.

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of PrPc antagonists effectively inhibits the suppression of long-term potentiation and improves both acute and spatial memory performance by blocking Aβ-oligomer binding to PrPc, providing a novel therapeutic approach for Alzheimer's disease with potential higher specificity and efficacy compared to existing treatments.

Implementation Method 1

Administration of PrPc antagonists, including soluble PrPc polypeptides, anti-PrPc antibodies

Methodology Applied

Scientific EffectAntibody-antigen binding:

Implementation Method 2

PrPc is required for Aβ-oligomer-induced synaptic dysfunction in vitro and in vivo

Methodology Applied

Scientific EffectReceptor-ligand interaction:

Implementation Method 3

PrPc antagonists... specifically target the cellular prion protein (PrPc) to inhibit Aβ-oligomer binding

Methodology Applied

Scientific EffectCompetitive inhibition:

Data Source

PatentUS9217036B2Prion protein as a receptor for amyloid-β oligomers

Publication Date: 2015.12.22 YALE UNIVERSITY

AI summary

The invention provides methods of inhibiting suppression of long term potentiation, improving acute memory retention and spatial memory performance and treating Alzheimer's disease by administration of a PrPc antagonist or combinations thereof. Additionally, this invention provides pharmaceutical kits comprising, and methods for making and using, such combinations, as well as methods of identifying molecules that could function as PrPc antagonists.